Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.